Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596232 · ClinicalTrials.gov registry record
Investigating Mucinase Activity in Airway Disease
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 211
- Enrollment target
NCT00596232: Completed study, sponsored by University of California, San Francisco.
NCT00596232 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 211 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596232 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how mucus (phlegm or spit) is broken down once it forms in the airways (bronchial tubes) of people with lung disease. This research study will also examine whether blood groups have an effect on lung function or the type of mucus found in the lung. This study is not designed to be a treatment for asthma, emphysema, cystic fibrosis, or other lung disease. It is designed to help the investigators learn more about the causes of airway disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2003-04 |
| Est. Completion | 2016-04 |
What the finished NCT00596232 record still lists
NCT00596232 is an observational study that tracks outcomes without assigning an intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00596232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00596232 about?
NCT00596232 is a clinical study titled "Investigating Mucinase Activity in Airway Disease". The purpose of this study is to investigate how mucus (phlegm or spit) is broken down once it forms in the airways (bronchial tubes) of people with lung disease. This research study will also examine whether blood groups have an effect on lung function or the type of mucus found in the lung. This st...
What is the current status of trial NCT00596232?
This trial is currently completed. The enrollment target is 211 participants. The study started on 2003-04. Estimated completion is 2016-04.
Who is sponsoring clinical trial NCT00596232?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia